On October 13, 2026, Zug-based medtech company NeuroGyn AG said it had closed a CHF 4 million Series A led by an unnamed Swiss institutional investor active in medical technology, alongside private investors. The money will fund the company's first human clinical studies, regulatory work, and progress toward commercializing PosStim, a minimally invasive pelvic neuromodulation platform. PosStim is built around the Genital Nerve Stimulation (GNS) procedure, and overactive bladder is its first clinical target. NeuroGyn was founded by Professor Marc Possover, who founded neuropelveology, the specialty focused on pelvic nerve disorders. The company says its aim is to make pelvic neuromodulation something gynecologists can offer, rather than leaving it only to specialist neurosurgical centers.

Why It Matters

Pelvic neuromodulation is becoming a small femtech-device category in its own right. NeuroGyn's round follows [FemPulse's CE mark](/stories/fempulse-ring-ce-mark-oab) in September for a self-inserted vaginal neuromodulation ring, also targeting overactive bladder. The two companies are taking different routes: FemPulse uses a wearable, while NeuroGyn uses a gynecologist-implanted lead on the genital nerve. Both start with bladder symptoms because the reimbursement codes and clinical endpoints already exist. The sexual-health potential is the longer-term option value. The pudendal and genital nerves that control continence also carry genital sensation and arousal signalling. If either company eventually shows effects on sexual function, it would compete with drugs and devices for both female arousal disorders and ED. That is years away, and the CHF 4M round is small. The founder's academic credibility makes this a company to track, not one to value on its ambitions yet.

The company's stated "broader vision" goes further. It wants to build pelvic bioelectronic medicine for women and men, with possible future applications including male erectile dysfunction and pelvic pain. NeuroGyn says these "will require dedicated clinical evaluation." PosStim is investigational, not approved and not for sale. One healthcare-transactions newsletter estimates the pre-money valuation at about CHF 48.3 million. That figure has not been disclosed by the company and should be treated as an estimate. GS MedTech's weekly funding tracker separately confirmed the round and the plan to move into human studies.

Sources

Update — 2026-10-26

Initial entry — story first created.